Experimental Induction of Hepatomas, Mammary Tumors, and Other Tumors With Metronidazole in Noninbred Sas:MRC(WI)BR Rats2

1 September 1979

journal article
research article
Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute

Vol. 63 (3) , 863-868
https://doi.org/10.1093/jnci/63.3.863

Abstract

Metronidazole, a chemotherapeutic agent against trichomonas infection, was tested for carcinogenicity in noninbred Sas:MRC(WI)BR rats. Three groups were given the drug for life at dose levels of 0.6%, 0.3%, and 0.06% in a powdered diet. The incidence of mammary tumors (P<0.020) and hepatomas (P<0.050) increased significantly among females given the highest dose (0.6%). Also, the rates of Leydig cell tumors of the testes (P<0.040) and pituitary adenomas (P<0.040) were statistically significant among males given the highest dose (0.6%). Results are discussed in light of a possible hazard of this drug to humans.

Keywords

This publication has 1 reference indexed in Scilit:

Hyperplastic and Early Neoplastic Lesions of the Liver in Buffalo Strain Rats of Various Ages Given Subcutaneous Carbon Tetrachloride2
JNCI Journal of the National Cancer Institute, 1967